PARIS (dpa-AFX) - French drug major Sanofi (SNYNF, SNY) announced Friday
that the U.S. Food and Drug Administration has accepted for Priority Review the
supplemental Biologics License Application or sBLA for Dupixent (dupilumab).

The sBLA is for Dupixent in a sixth potential indication as an add-on
maintenance treatment in certain adult patients with uncontrolled chronic
obstructive pulmonary disease or COPD.

The target action date for the FDA decision is June 27, 2024. The company noted
that regulatory submissions are also under review in China and the European
Union.

If approved, Dupixent would be the only biologic therapy for COPD and the first
new treatment approach for the disease in more than a decade, Sanofi said.

COPD is a respiratory disease that damages the lungs and causes progressive lung
function decline, with symptoms including persistent cough, breathlessness and
excessive mucus production.

The company said the Priority Review is granted based on positive results from
two Phase 3 trials.

The sBLA, along with other worldwide submissions, are supported by data from the
Phase 3 COPD clinical research program evaluating the efficacy and safety of
Dupixent in adults who were current or former smokers with uncontrolled COPD
with evidence of type 2 inflammation.

The primary endpoint was met in both trials of BOREAS and NOTUS, showing
Dupixent significantly reduced moderate or severe acute COPD exacerbations by
30% and 34% respectively, compared to placebo.

In both trials, Dupixent also rapidly and significantly improved lung function
compared to placebo, with improvements sustained at 52 weeks.

For More Such Health News, visit rttnews.com



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX